Compare Novo Nordisk A/S (NVO) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs PepsiCo, Inc. — how do they compare? Novo Nordisk A/S trades at $46.32 (market cap $207.85B), while PepsiCo, Inc. trades at $138.69 (market cap $188.91B). The key difference: Novo Nordisk A/S and PepsiCo, Inc. are close in size by market cap, and PepsiCo, Inc. pays the higher dividend (4.28%). Which is the better fit depends on your goals.
| NVO | PEP | |
|---|---|---|
Market Cap | $207.85B | $188.91B |
Sector | Health | Consumer Staples |
52-Week High | $63.98 | $170.44 |
52-Week Low | $35.29 | $134.95 |
Enterprise Value | $222.55B | $231.41B |
Dividend Yield | 3.81% | 4.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
PepsiCo (PEP) trades at $138.22, up 0.38% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $2.20 beating expectations of $2.19, and robust profitability metrics including 10.78% net income margin and 51.59% ROE. Recent news highlights price adjustments for snacks and sponsorship changes, while analysts maintain a cautious but generally positive outlook.
PepsiCo presents a stable investment case with strong cash flow generation and dividend consistency, though near-term headwinds include pricing sensitivity and competitive pressures. The consensus price target of $158.79 suggests 15% upside potential, supported by ongoing business optimization efforts. Key risks include consumer pushback on pricing and execution challenges in North American markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
